Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD8701 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD8701||AZD-8701|AZD 8701||AZD8701 is an antisense oligonucleotide that targets FOXP3 and modulates expression of its target genes, which potentially results in reduced immunosuppession (Cancer Res 2019;79(13 Suppl):Abstract nr 2713).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04504669||Phase I||AZD8701 + Durvalumab AZD8701||First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours||Recruiting|